AC Immune SA
2.61
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
2.61
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 2.6
Market Cap 260.17M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.42
PE Ratio (ttm) -6.21
Forward PE n/a
Analyst Buy
Ask 2.98
Volume 169,706
Avg. Volume (20D) 129,378
Open 2.64
Previous Close 2.61
Day's Range 2.60 - 2.83
52-Week Range 2.25 - 4.98
Beta undefined

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The comp...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2016
Employees 133
Stock Exchange NASDAQ
Ticker Symbol ACIU

Analyst Forecast

According to 2 analyst ratings, the average rating for ACIU stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 359.77% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

AC Immune SA is scheduled to release its earnings on Mar 13, 2025, before market opens.
Analysts project revenue of $556.43K, reflecting a -96.67% YoY shrinking and earnings per share of -0.19, making a 216.67% increase YoY.
2 months ago · Source
+13.42%
AC Immune shares are trading higher after the comp... Unlock content with Pro Subscription
4 months ago · Source
+5.81%
AC Immune shares are trading higher after the company announced it will receive the second ReTain-related milestone payment under its agreement with Janssen Pharmaceuticals.